心瓣膜疾病介入术中的慧眼——超声心动图的应用

经导管瓣膜治疗术如主动脉瓣置换术、二尖瓣钳夹术及三尖瓣置换术等已逐渐应用。超声心动图在心脏瓣膜病介入治疗前后能进行定性和定量诊断,具有重要价值。本文综述超声心动图技术在瓣膜病介入治疗中的应用现状与进展,以便指导临床实践。     

First in human percutaneous implantation of a balloon expandable transcatheter heart valve in a severely stenosed native mitral valve

Transcatheter implantation of a balloon expandable valve in calcified severely stenosed native mitral valves has recently been described. The two cases reported so far utilized the surgical transapical approach generally used for transapical transcatheter aortic valve replacement. A percutaneous approach has not been published. We report the first successful percutaneous implantation of a balloon expandable transcatheter valve in the native mitral valve without a surgical incision. © 2014 Wiley Periodicals, Inc.     

经皮球囊二尖瓣扩张术并发症的外科治疗

本院自１９８７年１０月至１９９５年９月，３５０例行经皮球囊二尖瓣成形术后发生并发症需要外科治疗的８例患者，其中心脏穿破致急性心包填塞３例、脑栓塞１例、创伤性重度二尖瓣关闭不全２例、创伤性房间隔缺损５例。外科采用紧急开胸止血、左心房血栓清除、修补创伤性房间隔缺损、二尖瓣置换、左径二尖瓣扩张术等治疗方法。作者认为：经皮球囊二尖瓣成形术后发生并发症，应及时采用适当的外科治疗措施，切勿延误治疗时机；经皮球囊二尖瓣成形术需有一定的适应证，不能完全替代二尖瓣置换术或直视二尖瓣成形术。     

Iatrogenic dissection of the ascending aorta during TAVI sealed with the corevalve revalving prosthesis

Transcatheter aortic valve implantation (TAVI) is rapidly becoming an accepted treatment option for a selected group of high risk or inoperable patients with severe aortic stenosis. However, this procedure is not without complications. We report a case of acute type A aortic dissection due to balloon aortic valvuloplasty during TAVI that was successfully sealed by the CoreValve prosthesis, thus avoiding surgical intervention.© 2011 Wiley‐Liss, Inc.     

经皮球囊二尖瓣成形术治疗风湿性二尖瓣狭窄疗效的初步探讨

【】目的 探讨经皮球囊二尖瓣成形术( PBMV) 治疗风湿性二尖瓣狭窄患者的近期疗效。方法 将我院2013 年9 月-2016 年01月14 例应用PBMV治疗的风湿性二尖瓣狭窄患者按照年龄分为A组(年龄＜60岁)、B组(年龄≥60岁),两组分别用心导管测定患者PBMV 前后的左心房压力、肺动脉压力,心脏超声评价PBMV 前后二尖瓣口面积、二尖瓣口血流速度、二尖瓣反流面积及左房内径、左室舒张末径、右房内径、右室舒张末径、左室每搏输出量、左室射血分数等指标。将两组数据进行统计分析。结果 PBMV成功率100%,无围手术期并发症及死亡病例。A组、B组在PBMV 前、后所有参数比较均无统计学意义(P＜0.05)。结论PBMV 治疗风湿性二尖瓣狭窄有效,高龄患者(≥60岁)亦可以从该术式获益。     

Simultaneous transapical transcatheter aortic valve replacement and transcatheter mitral valve replacement for native valvular stenosis

Transcatheter aortic valve replacement (TAVR) is well established for patients who cannot undergo surgery (Leon et al., N Engl J Med 2010;363:1597) or are high risk for surgery (Smith et al., N Engl J Med 2011;364:2187–2198). Experience with the TAVR procedure has led to recent reports of successful transcatheter mitral valve replacement (TMVR) procedures (Cheung et al., J Am Coll Cardiol 2014;64:1814; Seiffert et al., J Am Coll Cardiol Interv 2012;5:341–349) separately or simultaneously with the TAVR. However, these reports were of simultaneous valve‐in‐valve procedures (Cheung Anson, et al. J Am Coll Cardiol 2013;61:1759–1766). A recent report from Portugal also reported simultaneous transpical implantation of an inverted transcatheter aortic valve‐in‐ring in the mitral position and transcatheter aortic valve (Hasan et al., Circulation 2013;128:e74–e76). There has been an experience of TMVR only in native mitral valve for mitral valve stenosis, but none in both aortic and mitral valves. We report the first in human case of simultaneous transapical TAVR and TMVR in native valves secondary to valvular stenosis. Our patient was not a candidate for percutaneous balloon mitral valvuloplasty secondary to a high Wilkins Score. Sizing of the aortic valve was based on the transesophageal echocardiogram (TEE), whereas sizing of the mitral valve was based on TEE measurements and balloon inflation during left ventriculography. © 2015 Wiley Periodicals, Inc.     

First report on a human percutaneous transluminal implantation of a self-expanding valve prosthesis for interventional treatment of aortic valve stenosis.

BACKGROUND: Percutaneous aortic valve replacement is a new technology for the treatment of patients with significant aortic valve stenosis. We present the first report on a human implantation of a self-expanding aortic valve prosthesis, which is composed of three bovine pericardial leaflets inserted within a self-expanding nitinol stent. The 73-year-old woman presented with severe symptomatic aortic valve stenosis (mean transvalvular gradient of 45 mmHg; valve area of 0.7 cm2). Surgical valve replacement had been declined for the patient because of comorbidities, including previous bypass surgery. METHOD AND RESULTS: A retrograde approach via the common iliac artery was used for valve deployment. The contralateral femoral vessels were used for a temporary extracorporal circulation, unloading the left ventricle during the actual stent expansion. Clinical, hemodynamic, and echocardiographic outcomes were assessed serially during the procedure. Clinical and echocardiographic follow-up at day 1, 2, and 14 post procedure was performed to evaluate the short-term outcome. The prosthesis was successfully deployed within the native aortic valve, with accurate and stable positioning and with no impairment of the coronary artery or vein graft blood flow. 2D and doppler echo immediately after device deployment showed a significant reduction in transaortic mean pressure gradient (from 45 to 8 mmHg) without evidence of aortic or mitral valve insufficiency. The clinical status has then significantly improved. These results remained unchanged up to the day 14 follow-up. CONCLUSION: This case report demonstrates a successful percutaneous implantation of a self-expanding aortic valve prosthesis with remarkable functional and clinical improvements in the acute and short-term outcome.     

外科二尖瓣交界分离术后再狭窄二尖瓣球囊成形术

将６６例二尖瓣狭窄患者首次行ＰＢＭＶ和１８例外科分离术后再狭窄患者行ＰＢＭＶ进行比较，结果表明两者扩瓣治疗前、后的血流动力学指数有明显差异（Ｐ＜０．００１），但将两者术后相应的血流动力学指数进行比较差异无显著性（Ｐ＞０．０５）。说明外科二狭分离术后再狭窄患者成功地进行ＰＢＭＶ可显著改善临床症状，仍是一种有效的方法。     

One‐stop‐shop totally percutaneous approach for severe aortic and mitral regurgitation in cardiogenic shock

Patients presenting with cardiogenic shock and severe combined aortic and mitral regurgitation represent a major clinical challenge. Therapeutic options are limited in this setting as they are often deemed inoperable due to prohibitive risk for surgery, while mechanical circulatory support is usually contraindicated or technically challenging. Medical therapy, on the other hand, is associated with high‐mortality rates. Therefore, percutaneous therapies may represent an appealing alternative. Here, we present a “one‐stop‐shop” totally percutaneous approach for severe aortic and mitral regurgitation in a patient with cardiogenic shock.